EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death

Mohamed Abdelsalam iD, Melisa Halilovic, Ramy Ashry iD, Husam Nassar iD, Frank Erdmann iD, Matthias Schmidt iD, Oliver H Krämer iD, Wolfgang Sippl iD

Pharmaceuticals · 12.05.2026 · 19 (5) · 756

DOI: 10.3390/ph19050756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.05.2026. Verfasst von Mohamed Abdelsalam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Brigitte und Dr. Konstanze Wegener-Stiftung, José Carreras Leukämie-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Acute myeloid leukemia (AML) is a hematological malignancy frequently driven by mutations in the FLT3 gene, particularly internal tandem duplications (FLT3-ITD), which contribute to aberrant cell proliferation and resistance to tyrosine kinase inhibitors (FLT3i). The limitations of current FLT3i therapies, including drug resistance, off-target effects, and poor selectivity, necessitate the development of novel therapeutic strategies. Proteolysis-targeting chimeras (PROTACs) represent a promising approach to achieving degradation of oncogenic proteins.

Methods

We developed FLT3-targeting PROTACs based on the previously described compound MA49, with a focus on linker modifications to improve degradation efficiency and pharmacokinetic properties.

Results

Among these, compounds MA190 and MA191, containing rigid cyclohexyl-piperidine/piperazine linkers, demonstrate superior degradation of FLT3-ITD in MV4-11 AML cells at nanomolar concentrations, achieving >95% reduction in FLT3-ITD levels, outperforming MA49. In addition to improved kinase selectivity, good solubility, and plasma stability, MA190 and MA191 also exhibit excellent metabolic stability, whereas the predecessor PROTAC MA49 was unstable in microsomal assays. In cellular assays, MA190 and MA191 induce potent apoptosis in FLT3-ITD+ AML cells but have minimal effects on cells with wild-type FLT3. Proteomics reveal that MA191 also degrades MAPK14 (p38α), a kinase upregulated in leukemia, in addition to FLT3.

Conclusions

Dual targeting of FLT3-ITD and MAPK14 enhances proapoptotic signaling without any cytotoxic effect on normal human HEK293 cells. The co-inhibition using MA191 or a combination of doramapimod (a MAPK14 inhibitor) with a non-degrading FLT3 inhibitor result in greater caspase-3 activation than either treatment alone. This synergistic effect can be a therapeutic advantage, as several oncogenic drivers are switched off simultaneously by MA191.

Schlagwörter

Stichwörter der Autor:innen

FLT3-ITD mutationMAPK14 (p38α)PROTACsacute myeloid leukemiasynergistic effect

Autor:innen und Institutionen

  • Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle, Germany.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
  • Institute of Toxicology, University Medical Center, Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.

ORCID-Profile: Mohamed Abdelsalam, Ramy Ashry, Husam Nassar, Frank Erdmann, Matthias Schmidt, Oliver H Krämer, Wolfgang Sippl

Förderung

  • Deutsche Forschungsgemeinschaft
  • Brigitte und Dr. Konstanze Wegener-Stiftung
  • José Carreras Leukämie-Stiftung
  • Walter Schulz Stiftung
  • Deutsche José Carreras Leukämie-Stiftung
  • Dr. Werner Jackstädt-Stiftung
  • H.W & J. Hector Stiftung

Zitieren

APA

Abdelsalam, M., Halilovic, M., Ashry, R., Nassar, H., Erdmann, F., Schmidt, M., Krämer, O. H., & Sippl, W. (2026). Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death. Pharmaceuticals, 19(5), 756. https://doi.org/10.3390/ph19050756

Vancouver

Abdelsalam M, Halilovic M, Ashry R, Nassar H, Erdmann F, Schmidt M, et al. Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death. Pharmaceuticals. 2026;19(5):756. doi:10.3390/ph19050756

BibTeX
@article{Abdelsalam2026,
  author = {Abdelsalam, Mohamed and Halilovic, Melisa and Ashry, Ramy and Nassar, Husam and Erdmann, Frank and Schmidt, Matthias and Krämer, Oliver H and Sippl, Wolfgang},
  title = {Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {756},
  doi = {10.3390/ph19050756}
}
Kostenlos starten →